TNM002 / Guangzhou Trinomab Biotechnology - LARVOL DELTA

A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.

New P1 trial • Infectious Disease • Tetanus

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (clinicaltrials.gov) - P3 | N=675 | Completed | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2023 ➔ Mar 2023

Trial primary completion date • Infectious Disease • Tetanus

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (clinicaltrials.gov) - P3 | N=675 | Completed | Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Tetanus

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (clinicaltrials.gov) - P3 | N=675 | Active, not recruiting | Sponsor: Trinomab Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Tetanus

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Trinomab Biotech Co., Ltd.

New P1 trial

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (clinicaltrials.gov) - P3 | N=675 | Recruiting | Sponsor: Trinomab Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Tetanus

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus (clinicaltrials.gov) - P3 | N=675 | Not yet recruiting | Sponsor: Trinomab Biotech Co., Ltd.

New P3 trial • Infectious Disease • Tetanus

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers (clinicaltrials.gov) - P2 | N=240 | Completed | Sponsor: Trinomab Biotech Co., Ltd.

New P2 trial • Infectious Disease • Tetanus